The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2187 May 18, 2006 Number 20
NextNext

Cetuximab plus Radiotherapy for Head and Neck Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Bonner, J. A.
-PubMed Citation
To the Editor: The trial of cetuximab plus radiotherapy for locally advanced head and neck cancer, as reported by Bonner et al. (Feb. 9 issue),1 showed that patients with oropharyngeal squamous-cell carcinoma who received concomitant hyperfractionated radiotherapy obtained the greatest benefit from cetuximab. However, the study lacked adequate statistical power for subgroup analysis. Furthermore, the authors did not provide details regarding each radiotherapy regimen or primary sites in each group of patients in the trial.


Annie C. Ho, M.B., B.S., F.R.A.N.Z.C.R.
St. George Hospital
Kogarah, NSW 2217, Australia

  1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. [Free Full Text]
 
To the Editor: Cetuximab plus radiation appears to be of most benefit . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.